Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole benzoate, quantity: 64 mg/ml - oral liquid, suspension - excipient ingredients: ethanol; monobasic sodium phosphate; aluminium magnesium silicate; methyl hydroxybenzoate; sucrose; propyl hydroxybenzoate; orange oil terpeneless; flavour - anaerobic infections treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. notes. 1. because of the slow absorption and delayed peak plasma level, flagyl suspension is not recommended for use in the acute situation. 2. metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis( intestinal and extraintestin

Austraalia - inglise - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - calcium as calcium chloride hexahydrate - oral solution/suspension - calcium as calcium chloride hexahydrate mineral-calcium-salt active 13305.0 mg/100ml - nutrition & metabolism - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - calcium supplement | parturient paresis | hypocalcaemia | milk fever

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

viiv healthcare uk ltd - fosamprenavir calcium - oral suspension - 50mg/1ml

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - atenolol, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; propyl hydroxybenzoate; saccharin sodium; purified water; citric acid monohydrate; sorbitol solution (70 per cent) (non-crystallising); sodium citrate dihydrate; methyl hydroxybenzoate; flavour - all grades of hypertension including hypertension of renal origin.,frequent disabling angina without evidence of cardiac failure,cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those with acute myocardial infarction),myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; polysorbate 40; citric acid monohydrate; glycerol; purified water; carmellose sodium; ethanol; vanillin; carmoisine; sucrose; sunset yellow fcf; aluminium magnesium silicate; flavour - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery and in the treatment of certain cardiac arrythmias. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg/ml (equivalent: prednisolone, qty 5 mg/ml) - oral liquid, solution - excipient ingredients: disodium edetate; dibasic sodium phosphate; propyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; purified water; monobasic sodium phosphate; flavour - wherever corticosteroid therapy is indicated.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: purified water; benzoic acid; tartaric acid; sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: povidone; sodium propyl hydroxybenzoate; purified water; sodium methyl hydroxybenzoate; xanthan gum; glycerol; monobasic sodium phosphate dihydrate; sodium hydroxide; hydrochloric acid; sorbitol solution (70 per cent) (crystallising) - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - haloperidol, quantity: 2 mg/ml - oral liquid, solution - excipient ingredients: methyl hydroxybenzoate; purified water; propyl hydroxybenzoate; lactic acid - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - lopinavir, quantity: 80 mg/ml; ritonavir, quantity: 20 mg/ml - oral liquid, solution - excipient ingredients: ethanol absolute; glycerol; acesulfame potassium; sodium chloride; menthol; high fructose maize syrup; saccharin sodium; purified water; povidone; peg-40 hydrogenated castor oil; peppermint oil; propylene glycol; citric acid; sodium citrate dihydrate; flavour - kaletra is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older. this indication is based on the analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled clinical studies (see clinical trials).